發(fā)布時(shí)間：2018-02-04 14:16

  本文關(guān)鍵詞： 地西他濱 異基因造血干細(xì)胞移植 移植物抗宿主病　出處：《第三軍醫(yī)大學(xué)學(xué)報(bào)》2016年12期 　論文類(lèi)型：期刊論文

【摘要】：目的分析小劑量地西他濱(decitabine/dacogen,DAC)治療異基因造血干細(xì)胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)后慢性移植物抗宿主病(chronic graft versus host disease,c GVHD)患者的轉(zhuǎn)歸情況。方法收集2013年6月25日至2015年7月7日我院行alloHSCT術(shù)后早期復(fù)發(fā)及發(fā)生c GVHD,并接受小劑量DAC治療的4例患者,包括急性髓系白血病(acute myeloid leukemia,AML)3例,骨髓增生異常綜合征(myelodysplastic syndrome,MDS)1例。對(duì)其診斷、移植方式、c GVHD分型及評(píng)分、以及DAC治療后轉(zhuǎn)歸進(jìn)行分析。結(jié)果 4例接受小劑量DAC的患者,c GVHD癥狀減輕,無(wú)嚴(yán)重的血液學(xué)毒性。1例因嚴(yán)重肺部感染放棄治療,3例目前病情穩(wěn)定。結(jié)論小劑量DAC可減輕allo-HSCT術(shù)后c GVHD癥狀,改善患者生存質(zhì)量,并對(duì)早期復(fù)發(fā)的控制有一定的效果。
[Abstract]:Objective to analyze the low dose of decitabine / dacogen. Dacc was used to treat allogeneic hematopoietic stem cell transplantation. Chronic graft versus host disease after allo-HSCT. Methods from June 25th 2013 to July 7th 2015, patients with alloHSCT received early recurrence and c GVHD. Four patients were treated with low dose DAC, including 3 patients with acute myeloid leukemia. One case of myelodysplastic syndrome (MDS) with myelodysplastic syndrome (MDS). Results the symptoms of GVHD were alleviated in 4 patients who received low dose of DAC, and there was no serious hematological toxicity. 1 cases abandoned treatment because of severe pulmonary infection. Conclusion low dose DAC can alleviate the symptoms of c GVHD after allo-HSCT, improve the quality of life of the patients, and have a certain effect on the control of early recurrence.
【作者單位】： 第三軍醫(yī)大學(xué)新橋醫(yī)院全軍血液病中心;
【分類(lèi)號(hào)】：R457.7
【正文快照】： 軍血液病中心)Corresponding author:Kong Peiyan,E-mail:peiyankong@163.com地西他濱(decitabine/dacogen,DAC)作為甲基化轉(zhuǎn)移酶抑制劑,近年來(lái)在急性髓系白血病(acute mye-loid leukemia,AML)及骨髓增生異常綜合征(myelodys-plastic syndrome,MDS)等髓系腫瘤中的應(yīng)用越來(lái)越受

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 李杰平;曾東風(fēng);陳幸華;張曦;劉紅;王慶余;向茜茜;孔佩艷;;利妥昔單抗治療難治性廣泛cGVHD的療效觀察[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2011年11期

，

本文編號(hào)：1490414